277 related articles for article (PubMed ID: 22249701)
1. [Transarterial ablation of hepatocellular carcinoma. Status and developments].
Radeleff BA; Stampfl U; Sommer CM; Bellemann N; Hoffmann K; Ganten T; Ehehalt R; Kauczor HU
Radiologe; 2012 Jan; 52(1):44-55. PubMed ID: 22249701
[TBL] [Abstract][Full Text] [Related]
2. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments.
Gnutzmann D; Kortes N; Sumkauskaite M; Schmitz A; Weiss KH; Radeleff B
Minim Invasive Ther Allied Technol; 2018 Apr; 27(2):69-80. PubMed ID: 29381102
[TBL] [Abstract][Full Text] [Related]
3. New concepts in embolotherapy of HCC.
Pesapane F; Nezami N; Patella F; Geschwind JF
Med Oncol; 2017 Apr; 34(4):58. PubMed ID: 28299645
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
[TBL] [Abstract][Full Text] [Related]
5. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization.
Manas D; Bell JK; Mealing S; Davies H; Baker H; Holmes H; Hubner RA
Eur J Surg Oncol; 2021 Feb; 47(2):401-408. PubMed ID: 32958370
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
Lee EW; Khan S
Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
[TBL] [Abstract][Full Text] [Related]
8. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
9. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
10. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma.
Miraglia R; Pietrosi G; Maruzzelli L; Petridis I; Caruso S; Marrone G; Mamone G; Vizzini G; Luca A; Gridelli B
World J Gastroenterol; 2007 Jun; 13(21):2952-5. PubMed ID: 17589945
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
Facciorusso A
World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
[TBL] [Abstract][Full Text] [Related]
13. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
Chevallier O; Zhao K; Marinelli B; Yarmohammadi H
Chin Clin Oncol; 2023 Apr; 12(2):17. PubMed ID: 37081710
[TBL] [Abstract][Full Text] [Related]
14. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
[TBL] [Abstract][Full Text] [Related]
15. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
17. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.
Vogl TJ; Gruber-Rouh T
Dig Dis Sci; 2019 Apr; 64(4):959-967. PubMed ID: 30835030
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
Ludwig JM; Zhang D; Xing M; Kim HS
Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
[TBL] [Abstract][Full Text] [Related]
19. [Survival benefit with intraarterial techniques in hepatocellular carcinoma].
Sangro B
Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]